198 related articles for article (PubMed ID: 29206031)
1. Chemoselective Installation of Amine Bonds on Proteins through Aza-Michael Ligation.
Freedy AM; Matos MJ; Boutureira O; Corzana F; Guerreiro A; Akkapeddi P; Somovilla VJ; Rodrigues T; Nicholls K; Xie B; Jiménez-Osés G; Brindle KM; Neves AA; Bernardes GJL
J Am Chem Soc; 2017 Dec; 139(50):18365-18375. PubMed ID: 29206031
[TBL] [Abstract][Full Text] [Related]
2. A "tag-and-modify" approach to site-selective protein modification.
Chalker JM; Bernardes GJ; Davis BG
Acc Chem Res; 2011 Sep; 44(9):730-41. PubMed ID: 21563755
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the C2A domain of synaptotagmin-I and annexin-V as probes for detecting cell death.
Alam IS; Neves AA; Witney TH; Boren J; Brindle KM
Bioconjug Chem; 2010 May; 21(5):884-91. PubMed ID: 20402461
[TBL] [Abstract][Full Text] [Related]
4. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
[TBL] [Abstract][Full Text] [Related]
5. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents.
Bernardim B; Cal PM; Matos MJ; Oliveira BL; Martínez-Sáez N; Albuquerque IS; Perkins E; Corzana F; Burtoloso AC; Jiménez-Osés G; Bernardes GJ
Nat Commun; 2016 Oct; 7():13128. PubMed ID: 27782215
[TBL] [Abstract][Full Text] [Related]
6. Bioreducible comb-shaped conjugates composed of secondary amine and hydroxyl group-containing backbones and disulfide-linked side chains with tertiary amine groups for facilitating gene delivery.
Li RQ; Hu Y; Yu BR; Zhao NN; Xu FJ
Bioconjug Chem; 2014 Jan; 25(1):155-64. PubMed ID: 24328204
[TBL] [Abstract][Full Text] [Related]
7. A Chemical Probe for Dehydrobutyrine.
Chambers KA; Abularrage NS; Hill CJ; Khan IH; Scheck RA
Angew Chem Int Ed Engl; 2020 May; 59(19):7350-7355. PubMed ID: 32196905
[TBL] [Abstract][Full Text] [Related]
8. Bridging disulfides for stable and defined antibody drug conjugates.
Badescu G; Bryant P; Bird M; Henseleit K; Swierkosz J; Parekh V; Tommasi R; Pawlisz E; Jurlewicz K; Farys M; Camper N; Sheng X; Fisher M; Grygorash R; Kyle A; Abhilash A; Frigerio M; Edwards J; Godwin A
Bioconjug Chem; 2014 Jun; 25(6):1124-36. PubMed ID: 24791606
[TBL] [Abstract][Full Text] [Related]
9. Michael addition of amines and thiols to dehydroalanine amides: a remarkable rate acceleration in water.
Naidu BN; Sorenson ME; Connolly TP; Ueda Y
J Org Chem; 2003 Dec; 68(26):10098-102. PubMed ID: 14682706
[TBL] [Abstract][Full Text] [Related]
10. Post-translational mutagenesis for installation of natural and unnatural amino acid side chains into recombinant proteins.
Wright TH; Davis BG
Nat Protoc; 2017 Oct; 12(10):2243-2250. PubMed ID: 29532800
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
12. Site-specific antibody-drug conjugation through glycoengineering.
Zhou Q; Stefano JE; Manning C; Kyazike J; Chen B; Gianolio DA; Park A; Busch M; Bird J; Zheng X; Simonds-Mannes H; Kim J; Gregory RC; Miller RJ; Brondyk WH; Dhal PK; Pan CQ
Bioconjug Chem; 2014 Mar; 25(3):510-20. PubMed ID: 24533768
[TBL] [Abstract][Full Text] [Related]
13. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.
Staben LR; Koenig SG; Lehar SM; Vandlen R; Zhang D; Chuh J; Yu SF; Ng C; Guo J; Liu Y; Fourie-O'Donohue A; Go M; Linghu X; Segraves NL; Wang T; Chen J; Wei B; Phillips GD; Xu K; Kozak KR; Mariathasan S; Flygare JA; Pillow TH
Nat Chem; 2016 Dec; 8(12):1112-1119. PubMed ID: 27874860
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
[TBL] [Abstract][Full Text] [Related]
15. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway.
Meng L; Huang Z
Comput Biol Chem; 2018 Aug; 75():196-204. PubMed ID: 29803964
[TBL] [Abstract][Full Text] [Related]
16. General Dialdehyde Click Chemistry for Amine Bioconjugation.
Elahipanah S; O'Brien PJ; Rogozhnikov D; Yousaf MN
Bioconjug Chem; 2017 May; 28(5):1422-1433. PubMed ID: 28436674
[TBL] [Abstract][Full Text] [Related]
17. Chemo- and Regioselective Lysine Modification on Native Proteins.
Matos MJ; Oliveira BL; Martínez-Sáez N; Guerreiro A; Cal PMSD; Bertoldo J; Maneiro M; Perkins E; Howard J; Deery MJ; Chalker JM; Corzana F; Jiménez-Osés G; Bernardes GJL
J Am Chem Soc; 2018 Mar; 140(11):4004-4017. PubMed ID: 29473744
[TBL] [Abstract][Full Text] [Related]
18. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
19. PEGylation and HAylation via catechol: α-Amine-specific reaction at N-terminus of peptides and proteins.
Song IT; Lee M; Lee H; Han J; Jang JH; Lee MS; Koh GY; Lee H
Acta Biomater; 2016 Oct; 43():50-60. PubMed ID: 27424082
[TBL] [Abstract][Full Text] [Related]
20. PEGylation of native disulfide bonds in proteins.
Brocchini S; Balan S; Godwin A; Choi JW; Zloh M; Shaunak S
Nat Protoc; 2006; 1(5):2241-52. PubMed ID: 17406463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
